JP Morgan Chase
MNPR icon

JP Morgan Chase’s Monopar Therapeutics MNPR Stock Holding History

JP Morgan Chase’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$129K Buy
2,422
+313
+15% +$18.9K ﹤0.01% 5696
2025
Q4 		$138K Buy
2,109
+618
+41% +$50.5K ﹤0.01% 5722
2025
Q3 		$122K Sell
1,491
-430
-22% -$19.2K ﹤0.01% 5786
2025
Q2 		$68.7K Buy
1,921
+1,821
+1,821% +$66.1K ﹤0.01% 5774
2025
Q1 		$3.64K Sell
100
-1,937
-95% -$69.8K ﹤0.01% 6470
2024
Q4 		$44.8K Buy
+2,037
New +$34.2K ﹤0.01% 6055
2023
Q4 		– Sell
-1
Closed -$2 – 7738
2023
Q3 		$2 Buy
+1
New +$3 ﹤0.01% 7410
2023
Q2 		– Sell
-483
Closed -$3K – 7175
2023
Q1 		$3K Buy
+483
New +$7.15K ﹤0.01% 6347

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase's MNPR Position: Q1 2026 in Review

JP Morgan Chase increased its Monopar Therapeutics (MNPR) stake by 15% in Q1 2026, buying an estimated $18.9K and bringing the position to 2,422 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #5696.

JP Morgan Chase first reported a position in MNPR in Q1 2023 and has held it in 8 quarters since. The position peaked at $138K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • JP Morgan Chase held 2,422 shares of Monopar Therapeutics worth $129K as of Q1 2026.
  • JP Morgan Chase bought 313 Monopar Therapeutics shares in Q1 2026, an estimated $18.9K.
  • Monopar Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5696 holding.
  • JP Morgan Chase first reported a position in Monopar Therapeutics in Q1 2023 and has held it in 8 quarters since.
  • JP Morgan Chase's Monopar Therapeutics position peaked at $138K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.